Fremanezumab (TEV-48125)

Active substance

Fremanezumab (TEV-48125)

Holder

Teva Pharmaceuticals Europe

Status

Closed

Indication

patients with episodic migraine or chronic migraine who have successfully completed (per protocol) Study TV48125‐CNS‐30051 or the treatment phase of Study TV48125‐CNS‐30068.

Public documents

Approbation

Approbation amendment

Information for the patient

Informed consent

Last update

11/05/2021

Last updated on 13/02/2024